sellWeak cluster of 2
Benjamin Halladay sold $8 of ESPR
Chief Financial Officer at Esperion Therapeutics, Inc.. 8 shares at an average of $0.96, traded Apr 17, 2025, filed Apr 21, 2025.
Warning score
30Value
$8
8 shares
Holdings after
481,702
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- 0Trade size$8 at market
- 0Share of holdings soldSold 0.0% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001628280-25-018566, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | SOpen-market sale Common Stock | -8 | $0.96 | $8 | 481,702 | Apr 21, 2025 |
Related signals
Other insiders at Esperion Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Esperion Therapeutics, Inc. | Benjamin Looker General Counsel | $24k 6,517 shares | -2% | |
| 42Moderate | Esperion Therapeutics, Inc. | Benjamin Halladay Chief Financial Officer | $27k 7,337 shares | -2% | |
| 52Moderate | Esperion Therapeutics, Inc. | Sheldon L. Koenig President and CEO | $177k 48,244 shares | -3% | |
| 15Weak | ESPRsell Esperion Therapeutics, Inc. | Benjamin Looker General Counsel | $3,275 1,248 shares | -0% | |
| 49Moderate | Esperion Therapeutics, Inc. | Sheldon L. Koenig President and CEO | $79k 28,427 shares | -2% | |
| 30Weak | Esperion Therapeutics, Inc. | Benjamin Looker General Counsel | $18k 6,267 shares | -2% | |
| 37Weak | Esperion Therapeutics, Inc. | Benjamin Halladay Chief Financial Officer | $20k 7,046 shares | -1% | |
| 30Weak | Esperion Therapeutics, Inc. | Benjamin Halladay Chief Financial Officer | $12 11 shares | -0% | |
| 23Weak | Esperion Therapeutics, Inc. | Benjamin Looker General Counsel | $1,470 1,304 shares | -0% | |
| 37Weak | Esperion Therapeutics, Inc. | Benjamin Halladay Chief Financial Officer | $8,328 7,229 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.